Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Consumer Discretionary · ·
$0.85
▼ $0.03 (-3.0%)
Market data updated: 09/27 05:54 PM
Fundamentals updated: 09/27/2026
News analyzed: 09/27/2026
Market Cap
$143.14M
Day Range
$0.84 - $0.89
52-Week Range
$0.82 - $28.80
Beta
—
Next Earnings
—
Support
$0.14
Resistance
$1.45
NXXT is a stock from the Consumer Cyclical sector — Retail, automotive, and leisure — demand rises and falls with economic sentiment and consumers' disposable income.
-55.9% (1Y)
Strengths: 13/28 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 194.7%
Growth
Biggest negative driver
Operating margin
Operating margin: -85.8% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
58
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
60
Quality
58
Value
50
Momentum
81
Risk
26
Sentiment
80
Fundamental
30
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of NextNRG, Inc. highlights its expansion into Florida’s healthcare sector with a 25-year microgrid contract for Taft Medical Complex, reinforcing its AI-driven energy solutions. The company also reported a 40% revenue surge and narrowed losses in Q2 2026, alongside a 112.9 million-share resale registration. Analysts like HC Wainwright maintained a "Buy" rating but lowered their price target, while earnings calls emphasized growth and operational progress.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about NextNRG, Inc.. News trend score: 80. Reason: 7 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
70
🎯 Conviction (vs. Emotion)
41
Psychology
100
Fundamentals
30
Technical
81
Valuation
50
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+150%
Market Narrative
80
Fundamental Reality
41
Narrative Gap
+39
🔀 Weak-Conviction Rally
Price is moving, but not accompanied by a matching rise in news attention/sentiment.
🧠 StockIQ Psychologist
The market’s extreme loss aversion (score 100) reflects deep psychological resistance to further declines after a 62.2% drop over three months. This suggests investors are clinging to positions, avoiding downside risks despite modest volume activity. The narrative gap (12 points) hints at a disconnect between investor perceptions and market reality, possibly reinforcing caution. The key question is whether this aversion will sustain or if a catalyst—like a break in support—could trigger re-evaluation. Low FOMO and herding scores confirm no herd-driven momentum, while negative momentum and neutral RSI indicate no near-term euphoria.
Updated: 09/06/2026, 05:00 PM
What could change this?
👥 What the crowd believes
"Revenue Surges 40% and Losses Narrow as..."
"lowers the price target from $5 to $1.5"
"secured a 25-year Contract From Taft Medical Complex"
"reported quarterly losses of $(0.04) per share"
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 93/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock sparks a stark divide between growth-oriented and risk-averse methodologies. Peter Lynch and Charles Mackay both see strong potential, with Lynch calling it a ‘growth candidate’ where the price hasn’t fully reflected its upside, while Mackay notes no obvious signs of speculative mania. Meanwhile, cycle-focused investors like Howard Marks and Samuel Nelson also lean positive, viewing the stock as early-to-mid cycle and oversold relative to its fundamentals. However, Fisher and Smith temper enthusiasm, flagging it as solid but not exceptional or long-term worthy, while Marks (in his broader framework) warns of potentially inflated expectations. At the other end, Graham, Bagehot, and Loeb dismiss it outright—Graham lacks sufficient valuation data, Bagehot flags liquidity risks, and Loeb sees it as a capital-threatening gamble. Even passive or contrarian voices like Livermore and Housel reject it, with Livermore calling it a negative trend play and Housel noting its volatility would likely unsettle patient investors.
Peter Lynch
One Up on Wall Street (1989)
🟢 93
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 77
Positive trend — the price action Livermore looked for
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 65
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 45
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 39
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 36
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 35
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 33
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 20
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 19
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 13
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 0
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 15%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 0
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 0
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 286 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 3 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
8.4%
Operating Margin
-85.8%
Net Margin
-104.8%
EBITDA Margin
-82.9%
ROE
435.7%
ROA
-775.0%
ROIC
—
EPS
-$0.72
Cash
—
Total Debt
—
Current Ratio
0.11
Debt/Equity
—
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
-$0.16
Tangible Book Value per Share (Tangible NAV)
-$0.16
Sentiment based on basic keywords (not AI) — 7 positive, 11 neutral, 2 negative out of the last 20 articles.
ChartMill · 21.9.2026
ChartMill · 21.9.2026
ChartMill · 21.9.2026
Benzinga · 21.9.2026
ChartMill · 18.9.2026
Yahoo · 15.9.2026
Benzinga · 15.9.2026
Yahoo · 14.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
Yahoo · 26.8.2026
GlobeNewswire · 26.8.2026
Benzinga · 26.8.2026
MT Newswires · 24.8.2026
Motley Fool · 20.8.2026
Moby · 14.8.2026
Benzinga · 14.8.2026
GuruFocus.com · 14.8.2026
Zacks · 13.8.2026
GlobeNewswire · 13.8.2026
NextNRG, Inc. (NXXT) currently has a StockIQ AI score of 58/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
NXXT currently scores 58/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
NXXT's technical score is 81/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 194.7%; Earnings per share (EPS) growth: 87.9%; Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: Operating margin: -85.8% (negative); Net margin: -104.8% (negative); ATR: 13.9% of price.
StockIQ has no recorded dividend payment history for NXXT.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 15 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| FARKAS MICHAEL D | Gift | 18.6.2026 | 1,000,000 | -1,000,000 | — |
| FARKAS MICHAEL D | Gift | 18.6.2026 | 62,497,924 | -1,000,000 | — |
| FARKAS MICHAEL D | Grant/Award from Employer | 16.6.2026 | 260,000 | +260,000 | $0.39 |
| FARKAS MICHAEL D | Grant/Award from Employer | 16.6.2026 | 63,497,924 | +260,000 | $0.39 |
| FARKAS MICHAEL D | Grant/Award from Employer | 30.4.2026 | 21,739 | +21,739 | $1.83 |
| FARKAS MICHAEL D | Grant/Award from Employer | 30.4.2026 | 63,237,924 | +21,739 | $1.83 |
| FARKAS MICHAEL D | Grant/Award from Employer | 2.2.2026 | 21,739 | +21,739 | $1.83 |
| FARKAS MICHAEL D | Grant/Award from Employer | 2.2.2026 | 63,216,185 | +21,739 | $1.83 |
| Arbour Daniel Ronald | Open Market Sale | 30.12.2025 | 6,751 | -6,751 | $1.53 |
| Arbour Daniel Ronald | Open Market Sale | 30.12.2025 | 79,762 | -6,751 | $1.53 |
| Arbour Daniel Ronald | Open Market Sale | 29.12.2025 | 31,446 | -31,446 | $1.46 |
| Arbour Daniel Ronald | Open Market Sale | 29.12.2025 | 86,513 | -31,446 | $1.46 |
| Vaknin Avishai | Open Market Sale | 11.12.2025 | 15,000 | -15,000 | $2.00 |
| Vaknin Avishai | Open Market Sale | 11.12.2025 | 284,204 | -15,000 | $2.00 |
| Arbour Daniel Ronald | Open Market Sale | 9.12.2025 | 27,891 | -27,891 | $1.31 |
| Arbour Daniel Ronald | Open Market Sale | 9.12.2025 | 117,959 | -27,891 | $1.31 |
| Arbour Daniel Ronald | Open Market Sale | 5.12.2025 | 23,859 | -23,859 | $1.25 |
| Arbour Daniel Ronald | Open Market Sale | 5.12.2025 | 145,850 | -23,859 | $1.25 |
| Arbour Daniel Ronald | Open Market Sale | 1.12.2025 | 42,109 | -42,109 | $1.31 |
| Arbour Daniel Ronald | Open Market Sale | 1.12.2025 | 169,709 | -42,109 | $1.31 |
| FARKAS MICHAEL D | Grant/Award from Employer | 24.11.2025 | 1,000,000 | +1,000,000 | $1.04 |
| FARKAS MICHAEL D | Grant/Award from Employer | 24.11.2025 | 63,194,446 | +1,000,000 | $1.04 |
| Leibler Jack | Open Market Sale | 21.11.2025 | 150,000 | -150,000 | $1.03 |
| Leibler Jack | Open Market Sale | 21.11.2025 | 56,007 | -150,000 | $1.03 |
| Vaknin Avishai | Open Market Sale | 24.10.2025 | 509 | -509 | $2.04 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
621,465 shares short as of 2026-09-15 · vs. 4,203,124 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
55.8% of trading volume this week was short selling, vs. 53.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology